Aerie Pharmaceuticals (AERI) Receives Media Sentiment Score of 0.24
Media headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.6339404161715 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Key events next week – healthcare (continued #3) – ACADIA … – Seeking Alpha (seekingalpha.com)
- Aerie changes HQ to Durham, giving the Triangle another public company (finance.yahoo.com)
- Seaport Global Securities Comments on Aerie Pharmaceuticals Inc’s Q1 2018 Earnings (AERI) (americanbankingnews.com)
- Aerie Pharmaceuticals Inc (AERI) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Aerie Pharmaceuticals (AERI) Earns Buy Rating from Seaport Global Securities (americanbankingnews.com)
Shares of Aerie Pharmaceuticals (AERI) opened at $57.40 on Friday. The company has a market cap of $2,251.09, a price-to-earnings ratio of -14.10 and a beta of 0.98. Aerie Pharmaceuticals has a 1 year low of $38.14 and a 1 year high of $66.60. The company has a debt-to-equity ratio of 0.91, a quick ratio of 10.09 and a current ratio of 10.09.
AERI has been the topic of several recent research reports. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Seaport Global Securities initiated coverage on shares of Aerie Pharmaceuticals in a research note on Friday, January 26th. They issued a “buy” rating and a $78.00 price objective on the stock. Canaccord Genuity set a $73.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 18th. Cantor Fitzgerald set a $77.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 18th. Finally, BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $78.75.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.